Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Common Equity (2016 - 2025)

Sanofi (SNY) has disclosed Common Equity for 11 consecutive years, with $83.1 billion as the latest value for Q4 2025.

  • Quarterly Common Equity changed 0.32% to $83.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $83.1 billion through Dec 2025, changed 0.32% year-over-year, with the annual reading at $80.6 billion for FY2025, 3.87% down from the prior year.
  • Common Equity hit $83.1 billion in Q4 2025 for Sanofi, roughly flat from $82.8 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $83.1 billion in Q4 2025 to a low of $76.3 billion in Q4 2022.
  • Historically, Common Equity has averaged $80.1 billion across 5 years, with a median of $79.7 billion in 2023.
  • Biggest five-year swings in Common Equity: increased 4.42% in 2021 and later dropped 2.89% in 2022.
  • Year by year, Common Equity stood at $78.6 billion in 2021, then dropped by 2.89% to $76.3 billion in 2022, then increased by 4.41% to $79.7 billion in 2023, then rose by 3.97% to $82.8 billion in 2024, then increased by 0.32% to $83.1 billion in 2025.
  • Business Quant data shows Common Equity for SNY at $83.1 billion in Q4 2025, $82.8 billion in Q4 2024, and $79.7 billion in Q4 2023.